Ralph Alvarez bought $500K of Eli Lilly and (LLY)
Executed Aug 13 2025, disclosed Aug 14 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Aug 14 2025), the stock returned +14.4% (delay-adjusted); from the execution session (Aug 13 2025), +16.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Ralph Alvarez (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Eli Lilly and Company (LLY). Across 1 priced purchase filing, the average 21-session return was +16.5% from execution and +14.4% from disclosure (delay-adjusted; derived). The largest single filing was $500K of LLY (758 sh × $660.25, as filed), executed Aug 13 2025.
Healthcare · Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Jap…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→